NCT04262141View on ClinicalTrials.gov

IMG-7289 in Patients with Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Essential ThrombocythemiaPolycythemia Vera
Interventions
DRUG

IMG-7289

Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
collaborator

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

INDUSTRY

lead

Terrence J Bradley, MD

OTHER